Open Access

Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review)

  • Authors:
    • Yahya Alhamhoom
    • Homood M. As Sobeai
    • Sary Alsanea
    • Ali Alhoshani
  • View Affiliations

  • Published online on: April 14, 2022     https://doi.org/10.3892/ijo.2022.5355
  • Article Number: 65
  • Copyright: © Alhamhoom et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer‑related deaths remain a challenging and devastating obstacle to defeat despite the tremendous advances in cancer treatment. Cancer metastasis is the major cause of these cancer‑related deaths. Metastasis involves sequential steps during cancer cells' journey to a new site. These steps are coordinately regulated by specific intracellular regulators and cellular interactions between the cancer cells and the supporting microenvironment of the different organs. The development of aptamer‑based therapeutics is a promising strategy to fight cancer metastasis as it holds potential advantages. Oligonucleotide and peptide aptamers are short sequences of single‑stranded nucleic acids or amino acids, respectively, that target proteins, genetic materials, and cells. Antimetastatic aptamer‑based therapeutics exert their pharmacological effect by direct interaction with the signaling pathways inside the cancer cells or the communications between cancer cells and the tumor microenvironment. In addition, aptamers have been utilized as a guiding ligand to deliver a therapeutic moiety to cancer cells or the supporting microenvironment. The selected aptamer possesses high specificity since it is designed to recognize and interact with its target. This review summarizes recent advances in the development of aptamer‑based therapeutics targeting mediators of cancer metastasis. In addition, potential opportunities are discussed to inspire researchers in the field to develop novel aptamer‑based antimetastatic treatments.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 60 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Alhamhoom Y, As Sobeai HM, Alsanea S and Alhoshani A: Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review). Int J Oncol 60: 65, 2022.
APA
Alhamhoom, Y., As Sobeai, H.M., Alsanea, S., & Alhoshani, A. (2022). Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review). International Journal of Oncology, 60, 65. https://doi.org/10.3892/ijo.2022.5355
MLA
Alhamhoom, Y., As Sobeai, H. M., Alsanea, S., Alhoshani, A."Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review)". International Journal of Oncology 60.6 (2022): 65.
Chicago
Alhamhoom, Y., As Sobeai, H. M., Alsanea, S., Alhoshani, A."Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review)". International Journal of Oncology 60, no. 6 (2022): 65. https://doi.org/10.3892/ijo.2022.5355